Hanmi to lead cephalosporin antibiotic markets.

Published: 2007-09-03 06:57:00

Updated: 2007-09-03 06:57:00

Hanmi announced on Aug. 29 that the company had completed a plant exclusively for the production of the cephalosporin antibiotics at Pyeongtaek and obtained the KGMP certification from the KFDA on Aug. 24 in conformance to the global standards, which required for a separated plant to produce at n...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK